Clinical Trial

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

Study acronym: Vibrance-3
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets
Protocol Amendment History 4 changes
notable Enrollment increased: 96 -> 126 participants 2026-06-25
minor Trial arms changed: 4 -> 6 2026-06-25
notable Primary completion pushed: 2026-06 -> 2026-11 2026-06-25
minor Completion pushed: 2026-06 -> 2026-11 2026-06-25
Trial Details
NCT Number NCT06843590
Lead Sponsor Alkermes, Inc.
Conditions Idiopathic Hypersomnia
Enrollment 126 participants
Start Date 2025-05-22
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-24